Skip to content

Viking Therapeutics VKTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$130.96M-36.8%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$73.46M+3.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$96.5M+11.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$54.4M-7.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$49.94M-22.4%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$4.04B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Viking Therapeutics (VKTX) reported comprehensive income (loss), net of tax, attributable to parent of -$159.56M in Q1 2026.
How has Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 254.1% year-over-year, from -$45.06M to -$159.56M.
What is the long-term trend for Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Viking Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 59.4% compound annual growth rate (CAGR), from -$55.49M to -$358.47M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on securities and foreign currency adjustments. It provides a comprehensive view of the company's financial performance beyond traditional net income. Investors use this to assess the total impact of all economic events on the company's equity base.